aluates Reports

$ 0.0

Automative

Global Cell-Free Circulating Tumor DNA (ctDNA) Market Research Report 2025

Published Date: May 2025

Report Code: QYRE-Auto-2W15676

Global Cell Free Circulating Tumor DNA ctDNA Market Research Report 2023

BUY CHAPTERS

Global Cell-Free Circulating Tumor DNA (ctDNA) Market Research Report 2025

Code: QYRE-Auto-2W15676

Report

May 2025

Pages:91

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Nexomics

Roche

ORIOMICS

Signatera

Bio Rad

Biocartis

GuardantHealth

GSK

Astrazeneca plc

Neogenomics Laboratories

Amoydx

Annoroad

Burning Rock Biotech

Illumina Inc

Qiagen NV

Sysmex Corporation

Cell-Free Circulating Tumor DNA (ctDNA) Market

The global market for Cell-Free Circulating Tumor DNA (ctDNA) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Cell-free circulating tumor DNA (ctDNA) can act as a noninvasive cancer biomarker, offering a potential alternative to invasive tissue biopsies.

North American market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Cell-Free Circulating Tumor DNA (ctDNA) in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Cell-Free Circulating Tumor DNA (ctDNA) include Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis, QIAGEN, GuardantHealth, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Cell-Free Circulating Tumor DNA (ctDNA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell-Free Circulating Tumor DNA (ctDNA).

The Cell-Free Circulating Tumor DNA (ctDNA) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cell-Free Circulating Tumor DNA (ctDNA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cell-Free Circulating Tumor DNA (ctDNA) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Cell-Free Circulating Tumor DNA (ctDNA) Market Report

Report Metric	Details
Report Name	Cell-Free Circulating Tumor DNA (ctDNA) Market
Segment by Type	Gastric Cancer Methylation Screening Esophageal Cancer Methylation Screening Colorectal Cancer Methylation Screening Lung Cancer Methylation Screening Liver Cancer Methylation Screening Other Cancer Screening
Segment by Application	Hospital Medical Center Laboratory
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis, QIAGEN, GuardantHealth, GSK plc, AstraZeneca, NeoGenomics Laboratories, AmoyDx, Annoroad, Burning Rock Biotech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cell-Free Circulating Tumor DNA (ctDNA) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

Ans: The main players in the Cell-Free Circulating Tumor DNA (ctDNA) Market are Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis, QIAGEN, GuardantHealth, GSK plc, AstraZeneca, NeoGenomics Laboratories, AmoyDx, Annoroad, Burning Rock Biotech

What are the Application segmentation covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

Ans: The Applications covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report are Hospital, Medical Center, Laboratory

What are the Type segmentation covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

Ans: The Types covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report are Gastric Cancer Methylation Screening, Esophageal Cancer Methylation Screening, Colorectal Cancer Methylation Screening, Lung Cancer Methylation Screening, Liver Cancer Methylation Screening, Other Cancer Screening

Recommended Reports

Cell-Free DNA Markets

Cancer Diagnostics

Genetic & Liquid Biopsy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Gastric Cancer Methylation Screening

1.2.3 Esophageal Cancer Methylation Screening

1.2.4 Colorectal Cancer Methylation Screening

1.2.5 Lung Cancer Methylation Screening

1.2.6 Liver Cancer Methylation Screening

1.2.7 Other Cancer Screening

1.3 Market by Application

1.3.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Medical Center

1.3.4 Laboratory

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Perspective (2020-2031)

2.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Growth Trends by Region

2.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Region (2020-2025)

2.2.3 Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Region (2026-2031)

2.3 Cell-Free Circulating Tumor DNA (ctDNA) Market Dynamics

2.3.1 Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends

2.3.2 Cell-Free Circulating Tumor DNA (ctDNA) Market Drivers

2.3.3 Cell-Free Circulating Tumor DNA (ctDNA) Market Challenges

2.3.4 Cell-Free Circulating Tumor DNA (ctDNA) Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Revenue

3.1.1 Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Revenue (2020-2025)

3.1.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Players (2020-2025)

3.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Cell-Free Circulating Tumor DNA (ctDNA) Revenue

3.4 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Concentration Ratio

3.4.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Cell-Free Circulating Tumor DNA (ctDNA) Revenue in 2024

3.5 Global Key Players of Cell-Free Circulating Tumor DNA (ctDNA) Head office and Area Served

3.6 Global Key Players of Cell-Free Circulating Tumor DNA (ctDNA), Product and Application

3.7 Global Key Players of Cell-Free Circulating Tumor DNA (ctDNA), Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Cell-Free Circulating Tumor DNA (ctDNA) Breakdown Data by Type

4.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Type (2020-2025)

4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Type (2026-2031)

5 Cell-Free Circulating Tumor DNA (ctDNA) Breakdown Data by Application

5.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Application (2020-2025)

5.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2020-2031)

6.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2020-2025)

6.4 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2020-2031)

7.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2020-2025)

7.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2020-2031)

8.2 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2020-2025)

8.4 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2020-2031)

9.2 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2020-2025)

9.4 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2020-2031)

10.2 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2020-2025)

10.4 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Nexomics

11.1.1 Nexomics Company Details

11.1.2 Nexomics Business Overview

11.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.1.4 Nexomics Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.1.5 Nexomics Recent Development

11.2 Roche

11.2.1 Roche Company Details

11.2.2 Roche Business Overview

11.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.2.4 Roche Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.2.5 Roche Recent Development

11.3 ORIOMICS

11.3.1 ORIOMICS Company Details

11.3.2 ORIOMICS Business Overview

11.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.3.4 ORIOMICS Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.3.5 ORIOMICS Recent Development

11.4 Signatera

11.4.1 Signatera Company Details

11.4.2 Signatera Business Overview

11.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.4.4 Signatera Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.4.5 Signatera Recent Development

11.5 Illumina

11.5.1 Illumina Company Details

11.5.2 Illumina Business Overview

11.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.5.4 Illumina Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.5.5 Illumina Recent Development

11.6 Sysmex Corporation

11.6.1 Sysmex Corporation Company Details

11.6.2 Sysmex Corporation Business Overview

11.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.6.4 Sysmex Corporation Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.6.5 Sysmex Corporation Recent Development

11.7 Bio-Rad

11.7.1 Bio-Rad Company Details

11.7.2 Bio-Rad Business Overview

11.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.7.4 Bio-Rad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.7.5 Bio-Rad Recent Development

11.8 Biocartis

11.8.1 Biocartis Company Details

11.8.2 Biocartis Business Overview

11.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.8.4 Biocartis Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.8.5 Biocartis Recent Development

11.9 QIAGEN

11.9.1 QIAGEN Company Details

11.9.2 QIAGEN Business Overview

11.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.9.4 QIAGEN Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.9.5 QIAGEN Recent Development

11.10 GuardantHealth

11.10.1 GuardantHealth Company Details

11.10.2 GuardantHealth Business Overview

11.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.10.4 GuardantHealth Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.10.5 GuardantHealth Recent Development

11.11 GSK plc

11.11.1 GSK plc Company Details

11.11.2 GSK plc Business Overview

11.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.11.4 GSK plc Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.11.5 GSK plc Recent Development

11.12 AstraZeneca

11.12.1 AstraZeneca Company Details

11.12.2 AstraZeneca Business Overview

11.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.12.4 AstraZeneca Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.12.5 AstraZeneca Recent Development

11.13 NeoGenomics Laboratories

11.13.1 NeoGenomics Laboratories Company Details

11.13.2 NeoGenomics Laboratories Business Overview

11.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.13.4 NeoGenomics Laboratories Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.13.5 NeoGenomics Laboratories Recent Development

11.14 AmoyDx

11.14.1 AmoyDx Company Details

11.14.2 AmoyDx Business Overview

11.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.14.4 AmoyDx Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.14.5 AmoyDx Recent Development

11.15 Annoroad

11.15.1 Annoroad Company Details

11.15.2 Annoroad Business Overview

11.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.15.4 Annoroad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.15.5 Annoroad Recent Development

11.16 Burning Rock Biotech

11.16.1 Burning Rock Biotech Company Details

11.16.2 Burning Rock Biotech Business Overview

11.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.16.4 Burning Rock Biotech Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

11.16.5 Burning Rock Biotech Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Nexomics

Roche

ORIOMICS

Signatera

Bio Rad

Biocartis

GuardantHealth

GSK

Astrazeneca plc

Neogenomics Laboratories

Amoydx

Annoroad

Burning Rock Biotech

Illumina Inc

Qiagen NV

Sysmex Corporation

List of Tables

Table 1. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Gastric Cancer Methylation Screening

Table 3. Key Players of Esophageal Cancer Methylation Screening

Table 4. Key Players of Colorectal Cancer Methylation Screening

Table 5. Key Players of Lung Cancer Methylation Screening

Table 6. Key Players of Liver Cancer Methylation Screening

Table 7. Key Players of Other Cancer Screening

Table 8. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2020-2025) & (US$ Million)

Table 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2020-2025)

Table 12. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2026-2031)

Table 14. Cell-Free Circulating Tumor DNA (ctDNA) Market Trends

Table 15. Cell-Free Circulating Tumor DNA (ctDNA) Market Drivers

Table 16. Cell-Free Circulating Tumor DNA (ctDNA) Market Challenges

Table 17. Cell-Free Circulating Tumor DNA (ctDNA) Market Restraints

Table 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Players (2020-2025)

Table 20. Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-Free Circulating Tumor DNA (ctDNA) as of 2024)

Table 21. Ranking of Global Top Cell-Free Circulating Tumor DNA (ctDNA) Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by Cell-Free Circulating Tumor DNA (ctDNA) Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of Cell-Free Circulating Tumor DNA (ctDNA), Headquarters and Area Served

Table 24. Global Key Players of Cell-Free Circulating Tumor DNA (ctDNA), Product and Application

Table 25. Global Key Players of Cell-Free Circulating Tumor DNA (ctDNA), Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2020-2025) & (US$ Million)

Table 28. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2020-2025)

Table 29. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 30. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2026-2031)

Table 31. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2020-2025) & (US$ Million)

Table 32. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2020-2025)

Table 33. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 34. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2026-2031)

Table 35. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2020-2025) & (US$ Million)

Table 37. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2026-2031) & (US$ Million)

Table 38. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 39. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2020-2025) & (US$ Million)

Table 40. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2026-2031) & (US$ Million)

Table 41. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 42. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2020-2025) & (US$ Million)

Table 43. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2026-2031) & (US$ Million)

Table 44. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2020-2025) & (US$ Million)

Table 46. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2026-2031) & (US$ Million)

Table 47. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 48. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2020-2025) & (US$ Million)

Table 49. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2026-2031) & (US$ Million)

Table 50. Nexomics Company Details

Table 51. Nexomics Business Overview

Table 52. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 53. Nexomics Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 54. Nexomics Recent Development

Table 55. Roche Company Details

Table 56. Roche Business Overview

Table 57. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 58. Roche Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 59. Roche Recent Development

Table 60. ORIOMICS Company Details

Table 61. ORIOMICS Business Overview

Table 62. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 63. ORIOMICS Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 64. ORIOMICS Recent Development

Table 65. Signatera Company Details

Table 66. Signatera Business Overview

Table 67. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 68. Signatera Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 69. Signatera Recent Development

Table 70. Illumina Company Details

Table 71. Illumina Business Overview

Table 72. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 73. Illumina Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 74. Illumina Recent Development

Table 75. Sysmex Corporation Company Details

Table 76. Sysmex Corporation Business Overview

Table 77. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 78. Sysmex Corporation Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 79. Sysmex Corporation Recent Development

Table 80. Bio-Rad Company Details

Table 81. Bio-Rad Business Overview

Table 82. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 83. Bio-Rad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 84. Bio-Rad Recent Development

Table 85. Biocartis Company Details

Table 86. Biocartis Business Overview

Table 87. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 88. Biocartis Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 89. Biocartis Recent Development

Table 90. QIAGEN Company Details

Table 91. QIAGEN Business Overview

Table 92. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 93. QIAGEN Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 94. QIAGEN Recent Development

Table 95. GuardantHealth Company Details

Table 96. GuardantHealth Business Overview

Table 97. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 98. GuardantHealth Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 99. GuardantHealth Recent Development

Table 100. GSK plc Company Details

Table 101. GSK plc Business Overview

Table 102. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 103. GSK plc Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 104. GSK plc Recent Development

Table 105. AstraZeneca Company Details

Table 106. AstraZeneca Business Overview

Table 107. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 108. AstraZeneca Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 109. AstraZeneca Recent Development

Table 110. NeoGenomics Laboratories Company Details

Table 111. NeoGenomics Laboratories Business Overview

Table 112. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 113. NeoGenomics Laboratories Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 114. NeoGenomics Laboratories Recent Development

Table 115. AmoyDx Company Details

Table 116. AmoyDx Business Overview

Table 117. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 118. AmoyDx Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 119. AmoyDx Recent Development

Table 120. Annoroad Company Details

Table 121. Annoroad Business Overview

Table 122. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 123. Annoroad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 124. Annoroad Recent Development

Table 125. Burning Rock Biotech Company Details

Table 126. Burning Rock Biotech Business Overview

Table 127. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 128. Burning Rock Biotech Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025) & (US$ Million)

Table 129. Burning Rock Biotech Recent Development

Table 130. Research Programs/Design for This Report

Table 131. Key Data Information from Secondary Sources

Table 132. Key Data Information from Primary Sources

Table 133. Authors List of This Report

List of Figures

Figure 1. Cell-Free Circulating Tumor DNA (ctDNA) Picture

Figure 2. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type: 2024 VS 2031

Figure 4. Gastric Cancer Methylation Screening Features

Figure 5. Esophageal Cancer Methylation Screening Features

Figure 6. Colorectal Cancer Methylation Screening Features

Figure 7. Lung Cancer Methylation Screening Features

Figure 8. Liver Cancer Methylation Screening Features

Figure 9. Other Cancer Screening Features

Figure 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2020-2031) & (US$ Million)

Figure 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application: 2024 VS 2031

Figure 12. Hospital Case Studies

Figure 13. Medical Center Case Studies

Figure 14. Laboratory Case Studies

Figure 15. Cell-Free Circulating Tumor DNA (ctDNA) Report Years Considered

Figure 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region: 2024 VS 2031

Figure 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Players in 2024

Figure 20. Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-Free Circulating Tumor DNA (ctDNA) as of 2024)

Figure 21. The Top 10 and 5 Players Market Share by Cell-Free Circulating Tumor DNA (ctDNA) Revenue in 2024

Figure 22. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2020-2031)

Figure 24. United States Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2020-2031)

Figure 28. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. U.K. Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2020-2031)

Figure 36. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Australia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2020-2031)

Figure 44. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2020-2031)

Figure 48. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. UAE Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Nexomics Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 52. Roche Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 53. ORIOMICS Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 54. Signatera Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 55. Illumina Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 56. Sysmex Corporation Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 57. Bio-Rad Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 58. Biocartis Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 59. QIAGEN Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 60. GuardantHealth Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 61. GSK plc Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 62. AstraZeneca Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 63. NeoGenomics Laboratories Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 64. AmoyDx Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 65. Annoroad Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 66. Burning Rock Biotech Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2020-2025)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Circulating Tumor DNA Diagnostics Market Research Report 2025

Global ctDNA Detection Kit Market Research Report 2024

Global Circulating Tumour DNA ctDNA Testing Market Research Report 2024

Global ctDNA Detection Market Research Report 2025

Global Circulating Tumor DNA Test Kit Market Research Report 2024

Global Cell Free DNA cfDNA Testing Market Research Report 2024

Global Noninvasive Cancer Biomarkers Market Research Report 2024

Global Circulating Tumor Cell CTC Detection Market Research Report 2024

Global Liquid Biopsy Products Market Insights Forecast to 2030

ctDNA Methylation Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Microbial Cell free DNA mcfDNA Detection Market Research Report 2024

Global Free Circulating Tumor Cell Detection Market Research Report 2024

Global Cell Free DNA cfDNA Kits Market Research Report 2024

Circulating Tumor Cells CTC Liquid Biopsy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Circulating Tumor Cell CTC Detector Market Research Report 2024

Global Free DNA Extraction Kit Market Research Report 2024

Global Cell Free DNA cfDNA Blood Collection Tube Market Research Report 2024

Global Circulating Tumor Cells Market Research Report 2025

Global CTC Detection Market Research Report 2025

RELATED REPORTS

Global Fixation Device for Radiotherapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-4H16852

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Group A Streptococcus for Injection Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-37K16619

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Boron Neutron Capture Therapy System Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-30U16301

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Radioactive Glass Microsphere Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-2G16953

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions